Would you consider adjuvant olaparib in a patient with HER2+, high-risk, early stage breast cancer with germline BRCA mutation?  

OlympiA trial did not include her2+ breast cancer. 



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution